Trials / Conditions / Testicular Neoplasms

Testicular Neoplasms

21 registered clinical trials studyying Testicular Neoplasms — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Terminated	A Study of SGN-ALPV in Advanced Solid Tumors NCT05229900	Seagen Inc.	Phase 1
Recruiting	Lymphedema After Urologic Surgery NCT05264337	Vastra Gotaland Region	—
Completed	Effect of Online Education Given to Young Adults on Testicular Cancer Health Beliefs and Behaviors NCT05056688	Agri Ibrahim Cecen University	N/A
Completed	Role of Axumin PET Scan in Germ Cell Tumor NCT03426865	University of Texas Southwestern Medical Center	—
Withdrawn	Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy NCT02492360	Costantine Albany	—
Completed	Avelumab in Refractory Testicular Germ Cell Cancer. NCT03403777	National Cancer Institute, Slovakia	Phase 2
Terminated	CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physicia NCT02900248	CureOne	—
Terminated	Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors NCT02499952	Nasser Hanna, M.D.	Phase 2
Completed	Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumour NCT04122430	Walter and Eliza Hall Institute of Medical Research	—
Terminated	Testicular Cancer and Aerobic and Strength Training NCT02577172	Oslo University Hospital	N/A
Completed	High-Intensity Aerobic Interval Training in Testicular Cancer Survivors NCT02459132	University of Alberta	N/A
Completed	The Platinum Study Comparison Group NCT02890030	Lawrence Einhorn	—
Active Not Recruiting	Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer NCT02341989	St. Olavs Hospital	Phase 3
Unknown	Quality of Life Among Testicular Cancer Survivors NCT02304575	Rabin Medical Center	—
Recruiting	Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS NCT02229916	Dr. med. Christian Rothermundt	—
Completed	Engagement of Patients With Advanced Cancer NCT02966509	Stanford University	N/A
Completed	GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT) NCT06309732	Queen Mary University of London	Phase 2
Completed	High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II NCT00231582	Assistance Publique - Hôpitaux de Paris	Phase 2
Completed	Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence NCT00123773	AHS Cancer Control Alberta	Phase 2
Completed	Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors NCT02161692	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Phase 2
Completed	Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Tra NCT00001270	National Cancer Institute (NCI)	Phase 1